PUBLICATIONS

Hotspot testing for activating KRAS mutations is used in precision oncology to select colorectal cancer (CRC) patients who are eligible for anti-EGFR treatment. However, even for KRASwildtype tumors anti-EGFR response rates are <30%, while mutated-KRAS does not entirely rule out response, indicating the need for improved patient stratification.

Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found in approximately 5% of non-small cell lung carcinoma (NSCLC). Here, we present a comprehensive genomic landscape of 11 ALK+ NSCLC patients and investigate its relationship with response to crizotinib.

The molecular cancer registry Personalize My Treatment, managed by the Networks of Centres of Excellence nonprofit organization Exactis Innovation, is uniquely positioned to accelerate Canadian immuno-oncology (IO) research efforts throughout its national network of cancer sites.

Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expand personalized cancer treatment.